Literature DB >> 15241520

["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

V Schleyer1, S Meyer, M Landthaler, R-M Szeimies.   

Abstract

Mastocytoses are a heterogenous group of diseases characterized by proliferation and accumulation of mast cells in the skin and other organs. They are subdivided into cutaneous mastocytoses; systemic forms, which may appear with or without skin lesions; mast cell sarcomas and extracutaneous, localized, benign mastocytomas. Systemic mastocytoses apart from the skin mainly involve bone marrow, gastrointestinal tract, bones, lymph nodes, spleen and liver. Whereas indolent forms of systemic mastocytosis are mainly treated with antihistamines, glucocorticosteroids and PUVA therapy, the more aggressive forms, including mast cell leukemia, often require cytostatic chemotherapy. A 53-year old patient with beginning "smoldering systemic mastocytosis" failed to respond to high-dose systemic glucocorticosteroids and interferon-alpha. Treatment with cladribine led to an impressive improvement of skin lesions, a significant decrease in tryptase serum levels and stabilization of bone marrow infiltrates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241520     DOI: 10.1007/s00105-004-0733-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  19 in total

Review 1.  Treatment of cutaneous mastocytosis.

Authors:  Klaus Wolff
Journal:  Int Arch Allergy Immunol       Date:  2002-02       Impact factor: 2.749

2.  Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations.

Authors:  G Kolde; P J Frosch; B M Czarnetzki
Journal:  J Invest Dermatol       Date:  1984-09       Impact factor: 8.551

Review 3.  Treatment of mastocytosis: pharmacologic basis and current concepts.

Authors:  G Marone; G Spadaro; F Granata; M Triggiani
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

4.  Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

Authors:  M A Hoffman; D Janson; E Rose; K R Rai
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults.

Authors:  G Topar; C Staudacher; F Geisen; C Gabl; F Fend; M Herold; R Greil; P Fritsch; N Sepp
Journal:  Am J Clin Pathol       Date:  1998-03       Impact factor: 2.493

Review 6.  Nucleoside analogues in the treatment of haematological malignancies.

Authors:  S A Johnson
Journal:  Expert Opin Pharmacother       Date:  2001-06       Impact factor: 3.889

Review 7.  Mastocytosis: review of clinical and experimental aspects.

Authors:  K Hartmann; S B Bruns; B M Henz
Journal:  J Investig Dermatol Symp Proc       Date:  2001-11

Review 8.  Cladribine. Ortho Biotech Inc.

Authors:  C Tortorella; M Rovaris; M Filippi
Journal:  Curr Opin Investig Drugs       Date:  2001-12

9.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface.

Authors:  L Escribano; A Orfao; B Díaz Agustín; C Cerveró; S Herrero; J Villarrubia; P Bravo; A Torrelo; T Montero; M Valdemoro; J L Velasco; J L Navarro; J F San Miguel
Journal:  Cytometry       Date:  1998-10-15
View more
  1 in total

1.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.